Mepolizumab
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Mepolizumab: Thrombocytopenia due to immune destruction
One-Sentence Summary
Mepolizumab is an anti-IL-5 monoclonal antibody that depletes eosinophils. The TxGNN model (deep learning) predicts thrombocytopenia due to immune destruction as a new indication, with a score of 0.9966; this score may reflect similarities the model learned between related diseases, not biological evidence. The TxGNN model predicts it may be effective for thrombocytopenia due to immune destruction, but the current support is only 1 case report and no registered clinical trials, so this remains a computational prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Thrombocytopenia due to immune destruction |
| TxGNN Prediction Score | 0.9966 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Based on known information, mepolizumab is an anti-IL-5 monoclonal antibody that depletes eosinophils. Its role in eosinophil-driven disease is established, and mechanistically it might be applicable to conditions in which eosinophil-driven immune dysregulation contributes to disease.
The link to immune thrombocytopenia is weak. The only supporting publication is a case-level report in which mepolizumab, together with concomitant therapy, resolved a steroid-resistant hypereosinophilic immune diathesis with a mixed thrombotic microangiopathy. Any benefit on platelet counts would therefore be indirect, via control of eosinophil-driven immune dysregulation.
There is no evidence that IL-5 blockade acts on the core mechanisms of immune thrombocytopenia (autoantibody-mediated platelet clearance and impaired platelet production). The very high TxGNN score is a computational prediction only and should not be read as clinical support.
Other top-ranked predictions (primary release disorder of platelets, pseudo-von Willebrand disease, autoimmune thrombocytopenia, Glanzmann thrombasthenia, Evans syndrome, neonatal thrombocytopenia, autosomal thrombocytopenia with normal platelets, filariasis and mixed-type autoimmune haemolytic anaemia) have no clinical trials. Apart from a review of hypereosinophilic syndrome linked to the second-ranked prediction, they have no supporting literature either. Several of them (for example Glanzmann thrombasthenia and pseudo-von Willebrand disease) have no plausible link to IL-5 biology.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28648630 | 2018 | Case report | Blood Cells Mol Dis | Mepolizumab with concomitant therapy resolved a steroid-resistant hypereosinophilic immune diathesis and was associated with improvement of a mixed thrombotic microangiopathy (atypical haemolytic uraemic syndrome context) |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 12007Y | Nucala | Injection 100 mg in 1 mL single dose pre-filled pen | Not available in the data compiled for this report |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
No drug interactions were identified in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a computational score and a single case report in a different clinical context (hypereosinophilic syndrome with thrombotic microangiopathy). There are no trials, and there is no plausible mechanism linking IL-5 blockade to immune platelet destruction.
To proceed, the following is needed:
- Mechanism of action data (for example from DrugBank) to support a mechanistic-link analysis
- Warnings and contraindications from the TGA-approved Product Information, as safety screening cannot proceed without them
- Approved indication text for the ARTG entry
- Mechanistic or preclinical evidence that IL-5 blockade affects platelet destruction in immune thrombocytopenia
- A systematic literature search for further case series or studies in immune thrombocytopenia, particularly cases with coexisting eosinophilia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.